AstraZeneca | Results Presentation Deck | 40 slides

AstraZeneca · 2022-04
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON

Slide inventory

40
every slide · same image gating as the playbook
01
Slide 1
front_matter
Open slide detailBeat · Attention
02
other
Open slide detailBeat · Attention
03
front_matter
Open slide detailBeat · Attention
04
front_matter
Open slide detailBeat · Attention
05
The slide uses a three-column layout to categorize updates. Footer contains detailed methodology and definitions.summarize
Open slide detailBeat · Attention
06
Includes a footnote explaining changes in reporting for specific drugs (Koselugo, Andexxa).analyze_data
Open slide detailBeat · NeedLoop · Pattern Hunter
07
Includes a detailed list of abbreviations in the footer.summarize
Open slide detailBeat · NeedLoop · Pattern Hunter
08
front_matter
Open slide detailBeat · NeedLoop · Pattern Hunter
09
The table includes a breakdown of revenue, operating expenses, and profitability metrics.analyze_data
Open slide detailBeat · NeedLoop · Pattern Hunter
10
The slide highlights operating leverage by comparing revenue growth (60%) to operating profit growth (60%) and EPS growth (20%).analyze_data
Open slide detailBeat · NeedLoop · Pattern Hunter
11
The slide uses a split layout with financial targets on the left and qualitative drivers on the right.summarize
Open slide detailBeat · Satisfaction
12
The waterfall chart illustrates the bridge between two net debt figures.analyze_data
Open slide detailBeat · Satisfaction
13
Features headshots of Dave Fredrickson and Susan Galbraith alongside a molecular visualization.introduce_nominees
Open slide detailBeat · Satisfaction
14
The chart shows revenue breakdown by product over time from 2020 Q1 to 2022 Q1.analyze_data
Open slide detailBeat · Satisfaction
15
Includes ASCO 2022 conference branding and clinical trial abbreviations.summarize
Open slide detailBeat · Satisfaction
16
Includes detailed trial design diagrams for EMERALD-3 and SAFFRON studies.summarize
Open slide detailBeat · SatisfactionLoop · Golden Circle
17
The slide uses a three-column layout to summarize distinct therapeutic areas.summarize
Open slide detailBeat · SatisfactionLoop · Golden Circle
18
Features headshots of two executives and a molecular illustration.introduce_nominees
Open slide detailBeat · SatisfactionLoop · Golden Circle
19
Includes footnotes regarding reporting changes and definitions of acronyms.analyze_data
Open slide detailBeat · SatisfactionLoop · Golden Circle
20
Includes detailed footnotes regarding pro-forma growth calculations and definitions of acronyms.analyze_data
Open slide detailBeat · SatisfactionLoop · Golden Circle
21
Includes clinical trial charts for AZD8233 and eplontersen, alongside a list of regulatory milestones.analyze_data
22
Slide presents two Kaplan-Meier style survival/event curves alongside key efficacy metrics.analyze_data
23
introduce_nominees
24
The chart shows revenue breakdown by product for 2021 Q3, Q4 and 2022 Q1.analyze_data
25
Slide compares pricing dynamics (waterfall chart) and patient segmentation (concentric circles) for Ultomiris vs Soliris.analyze_data
26
The slide uses a split layout: left side details R&D strategy (LCM vs NME), right side provides a timeline of upcoming regulatory/clinical milestones.summarize
27
Includes corporate branding and imagery of the CEO and headquarters.state_next_steps
Open slide detailBeat · Action
28
The slide uses a matrix structure where rows are event types and columns are time periods.summarize
Open slide detailBeat · Action
29
The slide uses a four-column layout to categorize growth drivers.summarize
Open slide detailBeat · Action
30
introduce_nominees
Open slide detailBeat · Action
31
appendix
Open slide detailBeat · Action
32
The slide provides a detailed regional revenue breakdown for two key oncology products.analyze_data
Open slide detailBeat · Action
33
The slide presents two distinct charts: a stacked bar chart for regional product revenue and a stacked bar chart for collaboration revenue types.analyze_data
Open slide detailBeat · Action
34
The slide displays two stacked bar charts with corresponding data tables below each chart.analyze_data
Open slide detailBeat · Action
35
The slide displays three stacked bar charts with corresponding data tables below each chart.analyze_data
Open slide detailBeat · Action
36
Data tables included below each bar chart for clarity.analyze_data
Open slide detailBeat · Action
37
Data presented in stacked bar charts with corresponding data tables below each chart.analyze_data
Open slide detailBeat · Action
38
The data reflects revenue post-acquisition of Alexion by AstraZeneca starting Q3 2021.analyze_data
Open slide detailBeat · Action
39
The slide uses a three-column layout to categorize ESG metrics, with footnotes providing detailed methodology and scope definitions.summarize
Open slide detailBeat · Action
40
other
Open slide detailBeat · Action